A rising cancer incidence combined with the limitations of conventional
therapies, mean that Onyvax's approach to cancer treatment is addressing
significant markets and major unmet medical needs.
467,000 new cases of prostate cancer are diagnosed
per year in the US, Europe and Pacific Rim. (American Cancer
Society
(2003) and International Agency for Research on Cancer (WHO),
GLOBOCAN 2000)
Cases of prostate cancer in the UK increased 25%
between 1995 – 2000.
(UK Association of Cancer Registries)
For men with prostate cancer who have become resistant
to hormone therapy, median survival is typically less than
24 months. No treatment currently
available has been shown to prolong life for men with
prostate cancer who have not developed metastatic disease
119,000 new cases of ovarian cancer are diagnosed per year
in the US, Europe and Pacific Rim. (American Cancer Society (2003)
and International Agency for Research on Cancer (WHO), GLOBOCAN 2000).
